* On September 03, 2026, The FDA Seeks Public Input to Advance Development of Botanical Drug Products. The FDA issue Request for Information (RFI) to gather public input on opportunities to advance the development of botanical drug products. Read more.....
* On August 27, 2026 - Congresswoman Lauren O. BOEBERT Introduces Advancing Botanical Drug Development Act of Year-2026 (H.R. 10150) to provide a 12-years market exclusivity period for FDA-Approved Botanical Drugs. Read more.....
* On June 04, 2026, Google Developer Team and September 06, 2026, Apple Store Connect has been accepted for NutraCoin App to install in Google Play and Apple Store - Nutracoin is a digital platform designed to help investors manage their NutraCoin GSN balance in one secure and simple place. Users can view their token balance, track account activity, and manage buy/sell requests through the app. The platform is built for easy access, transparency, and future blockchain integration. Read more..... Google Play and Apple Store.
* On December 02, 2025, FDA inspection Golden Sunrise Nutraceutical facilities, classified as No Action Indicated (NAI), and FDA Establishment Inspection Report No.: 3014549624. Martin F. LOEFFLER (Loeffler) and Huu S. TIEU (Mr. Tieu) were present during inspection and closeout interview. As quoted by the FDA Inspection Affidavit signed by Mr. Tieu on December 16, 2025, stating "I attest that the firm's customers consist of medical groups and doctors throughout the United States which purchase the firm's products via healthcare and using value-based healthcare incentives for physicians to treat patients with chronic conditions such as various cancer or other various stages of Serious or Life-threatening diseases." Read more.....
* On October 20, 2025, Case No.: 1:20-cv-01060-DJC-SKO, Judge Daniel J. CALABRETTA ordered in favor of the Federal Trade Commission (FTC) against Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise), Mr. Tieu, and Stephen R. MEIS Motion for Summary Judgment and Permanent Injunction was GRANTED. Golden Sunrise is still allowed to continue doing business without paying a civil penalty to the FTC and without returning money to consumers. CASE CLOSED.
* On June 23, 2025, Anthem Blue Cross pays for Cellular Therapy treatment for Life-threatening situations to Oakview Medical Group. The Federal Food, Drug, and Cosmetic Act (FD&C Act) Title 21 U.S.C. §352(a)(1).......drugs or devices for coverage or reimbursement, shall not be considered to be false or misleading under this paragraph if the Health Care Economic Information relates to an indication approved under section 355, 360(k), 360c(f)(2), or 360e. Read more.....
* On June 20, 2025, U.S. Securities and Exchange Commission (SEC) has been accepted Golden Sunrise Nutraceutical, Inc. (Golden Sunrise) submission and CIK No.: 0001705521 as a Regulation Form D Rule 506(c). The SEC has successfully received notice of an exemption Golden Sunrise Private Placement Offering. Read more.....
* On January 18, 2025, Cigna Health and Life Company pays for Cellular Therapy treatment for chronic conditions to Oakview Medical Group. The Federal Food, Drug, and Cosmetic Act (FD&C Act) Title 21 U.S.C. §352(a)(1).......drugs or devices for coverage or reimbursement, shall not be considered to be false or misleading under this paragraph if the Health Care Economic Information relates to an indication approved under section 355, 360(k), 360c(f)(2), or 360e. Read more.....
* On November 05, 2024, FDA inspection Golden Sunrise Nutraceutical facilities. Martin F. LOEFFLER (Mr. Loeffler) President and Huu S. TIEU (Mr. Tieu) was the present during closeout interview "No objectionable conditions were discussed and Form FDA-483 was not issued." As quoted by the FDA Inspection Affidavit signed by Mr. Loeffler on November 21, 2024, stating "The dietary supplements are given to treat patients in various of Serious or Life-threatening diseases, including different stages of Cancer."
* On June 12, 2024, Case No.: 1:20-cr-00109-BAM-1, Magistrate Judge Barbara A. McAuliffe ordered Court made findings and imposed the sentencing Huu S. TIEU as to Counts I, II, and III, all to be served consecutively, for a total term of 18-months. Supervised Release: 12-months on Counts I, II, and III, all to be served concurrently, for a total term 12-months with standard and special conditions. Fine: Ten thousand ($10,000.00) dollars. Special Assessment: seventy-five ($75.00) dollars. Appeal rights given. Oral motion by the government to dismiss the indictment was GRANTED. Government waived right to seek forfeiture. CASE CLOSED.
* On July 31, 2020, the U.S. Federal Trade Commission (FTC) sued Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise), Huu S. TIEU, and Stephen R. MEIS for selling fake, expensive treatment plans that falsely claimed to cure COVID-19, Cancer, and Parkinson's disease. Read more.....
* On July 09, 2020, Case No.: 1:20-cr-0109-DAD-BAM the U.S. Attorney's Office Eastern District of California an indictment was filed charging Huu S. TIEU with three counts of mail fraud in violation. Read more.....
* On September 16, 2020, the FDA Consumer Safety Officer forward Golden Sunrise Nutraceutical (Golden Sunrise) products Center for Biologics Evaluation and Research (CBER) to the FDA Product Jurisdiction Officer to determine the jurisdiction of Golden Sunrise products.
* On September 14, 2020, the FDA COVID-19 Product Development Team assigned Prioritized Review Expedited No.: 2020-2867 CR2020-2596 to Golden Sunrise Pharmaceutical/Golden Sunrise Nutraceutical (Golden Sunrise) and FDA requested COVID-19 patient medical results. Golden Sunrise submitted fifty-four COVID-19 patient medical results for evaluation and classification of Golden Sunrise products.
* On August 26, 2020, the FDA COVID-19 Product Development Team requesting the COVID-19 patient medical results from Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise) to expedited review and classification. The COVID-19 Product Development Team stated "Please refer to Tracking No.: 435 when you respond."
* On April 09, 2020, Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise) submitted a letter to FDA Request for Designation and notification Emergency D-Virus Plan of Care treatment of COVID-19.
* On April 05, 2020, the FDA COVID-19 Product Development Team assigned the Tracking No.: 435 and Triaged to Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise).
* On April 03, 2020, Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise) submitted supplemental New Drug Application (sNDA) No.: 701204 under section Proposed Indication for Use: COVID-19 and Serious or Life-threatening conditions to FDA COVID-19 Product Development Team.
* On March 30, 2020, the FDA formally established Coronavirus Treatment Accelerate Program (CTAP), an emergency program designed to expedite the development of safe and effective treatments for patients fighting COVID-19. During this public health emergency associated with the COVID-19 pandemic, the Office of Combination Products (OCP) is requesting applications/sponsors to submit Request for Designation (RFDs), and Pre-RFDs electronically. The OCP issues classification and jurisdiction assignments for human medical products. The classification of a product determines the type of a product or combination of products. Jurisdiction determines the FDA Center or Lead Center (CBER, CDER, or CDRH) that will regulate the product.
* On February 19, 2019, FDA inspection Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise) facilities and classified as Voluntary Action Indicated (VAI). FDA Establishment Inspection Report No.: 3012327979, Huu S. TIEU (Mr. Tieu) President was the only person present during the closeout interview "No objectionable conditions were discussed and For FDA-483 was not issued." Mr. Tieu signed an affidavit dated March 22, 2019.
* On November 05, 2018, Golden Sunrise Pharmaceutical submitted the New Drug Application (NDA) No.: 701204 under section Proposed Indication for Use: Serious or Life-threatening conditions to FDA Regenerative Medicine Advanced Therapy (RMAT) Team, the submission triggers a rigorous evaluation process that includes a mandatory manufacturing and facility evaluation know as a Pre-Approval Inspection (PAI).
* On May 10, 2017, U.S. Securities and Exchange Commission (SEC) has been accepted Golden Sunrise Pharma, Inc. (Golden Sunrise) submission and CIK No.: 0001705521 as a Regulation Form D Rule 506(b). The SEC has successfully received notice of an exemption Golden Sunrise Private Placement Offering. Read more.....
** On December 13, 2016, President Barack H. OBAMA signed the 21th Century Cures Act into law to speed up new medical product development and delivery of new medical treatments to patients faster. The bill incorporated the Helping Families In Mental Health Crisis Act, first introduced by then-Congressman Tim F. MURPHY. Read more.....
REFERENCE
* On March 04, 2016, the FDA assigned to Golden Sunrise Pharmaceutical the New Drug Application (NDA) No.: 204701 to identify each formal marketing application for a new drug.
* On April 19, 2013, the FDA assigned a Pre-Investigational New Drug (Pre-IND) No.: 117507 under the regulation of the U.S. Federal, Drug, and Cosmetic Act (FD&C Act) Title 21 Section 505(b)(1). FDA stated "Once you have successfully addressed all the items listed above and below, you may be able to conduct a small well-designed study in a few patients."
* On February 22, 2010, the FDA assigned a Pre-Investigational New Drug (Pre-IND) Consultation meeting for a formal advisory consultation before submitting an Investigational New Drug (IND) application for evaluation process and classification.
* On November 15, 2007, Huu S. TIEU (Mr. Tieu) submitted a letter to the U.S. Food and Drug Administration (FDA) for a meeting regarding an evaluation of the New Medical Innovation products to treat patients in Life-threatening situations.
Copyright 2026 Golden Sunrise Nutraceutical - All Rights Reserved.